...
首页> 外文期刊>Physiological Research >Is Severe Pulmonary Hypertension a Contraindication for Orthotopic Heart Transplantation? Not Any More
【24h】

Is Severe Pulmonary Hypertension a Contraindication for Orthotopic Heart Transplantation? Not Any More

机译:严重的肺动脉高压是否会成为原位心脏移植的禁忌症?不再

获取原文
获取原文并翻译 | 示例
           

摘要

Pulmonary hypertension (PH) unresponsive to pharmacological intervention is considered a contraindication for orthotopic heart transplantation (OHTX) due to risk of postoperative right-heart failure. In this prospective study, we describe our experience with a treatment strategy of improving severe PH in heart transplant candidates by means of ventricular assist device (VAD) implantation and subsequent OHTX. In 11 heart transplantation candidates with severe PH unresponsive to pharmacological intervention we implanted VAD with the aim of achieving PH to values acceptable for OHTX. In all patients we observed significant drop in pulmonary pressures, PVR and TPG (p<0.001 for all) 3 months after VAD implantation to values sufficient to allow OHTX. Seven patients underwent transplantation (mean duration of support 216 days) while none of patients suffered right-side heart failure in postoperative period. Two patients died after transplantation and five patients are living in very good condition with a mean duration of 286 days after OHTX. In our opinion, severe PH is not a contraindication for orthotopic heart transplantation any more.
机译:由于术后右心衰竭的风险,对药理干预无反应的肺动脉高压(PH)被认为是原位心脏移植(OHTX)的禁忌症。在这项前瞻性研究中,我们描述了通过心室辅助装置(VAD)植入和随后的OHTX改善心脏移植候选者严重PH值的治疗策略的经验。在11位严重PH对药理反应无反应的心脏移植候选患者中,我们植入了VAD,目的是使PH达到OHTX可接受的值。在所有患者中,我们发现在VAD植入后3个月,肺压,PVR和TPG显着下降(所有P均<0.001)至足以允许OHTX的值。 7例患者接受了移植(平均支持时间216天),而术后无一例发生右侧心力衰竭。两名患者在移植后死亡,五名患者状况良好,OHTX后平均持续时间为286天。我们认为,严重的PH不再是原位心脏移植的禁忌症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号